Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Microcrystalline cellulose and methylcellulose are pharmaceutical excipients used in combination as a placebo in the iPACK-HD (Inhibit Progression of Coronary Artery Calcification With Vitamin K in HemoDialysis Patients) study. Led by Dr. Rachel Holden at Queen's University, this Phase 2 clinical trial evaluated the efficacy of high-dose vitamin K1 (phylloquinone) in reducing the progression of coronary artery calcification in patients receiving hemodialysis. The microcrystalline methylcellulose formulation was designed to be identical in appearance to the 10mg vitamin K1 tablets and was administered orally three times weekly over a 12-month period to the control group. As a placebo, the substance is intended to be biologically inert and does not possess a therapeutic mechanism of action for cardiovascular or renal diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microcrystalline cellulose + methylcellulose.